World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
90
Citations
81865
World Ranking
11937
National Ranking
1128

Andrew Tutt publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Andrew Tutt sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 319 publications — 21st percentile

21% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Andrew Tutt D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Andrew Tutt sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 90 D-Index — 41st percentile

41% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Andrew Tutt is affiliated with the Institute of Cancer Research in the United Kingdom. Their research primarily spans the fields of Biochemistry, Genetics and Molecular Biology, and Medicine, with a concentration on Oncology, Molecular Biology, Cancer Research, Genetics, and Pulmonary and Respiratory Medicine.

The scientist's research topics include:

  • PARP inhibition in cancer therapy
  • DNA Repair Mechanisms
  • BRCA gene mutations in cancer
  • Cancer Genomics and Diagnostics
  • Cancer Immunotherapy and Biomarkers
  • CRISPR and Genetic Engineering
  • Advanced Breast Cancer Therapies

Andrew Tutt has published extensively in the following venues:

  • Cancer Research
  • Annals of Oncology
  • npj Breast Cancer
  • Clinical Cancer Research
  • Journal of Clinical Oncology

Frequent co-authors with whom they have collaborated include:

  • Syed Haider
  • Stephen J. Pettitt
  • Christopher J. Lord
  • Judith M. Bliss
  • Rachel Brough

Some of the recent papers authored by Andrew Tutt include:

  • Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer, 2021, New England Journal of Medicine
  • Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up, 2023, Annals of Oncology
  • Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer, 2022, Annals of Oncology
  • Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance, 2021, Nature Communications
  • Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13,864 women in seven randomised trials, 2021, The Lancet Oncology

Best Publications

  • Signatures of mutational processes in human cancer

    Ludmil B. Alexandrov;Serena Nik-Zainal;Serena Nik-Zainal;David C. Wedge;Samuel A. J. R. Aparicio

  • Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

    Hannah Farmer;Nuala McCabe;Christopher J. Lord;Andrew N. J. Tutt;Andrew N. J. Tutt

  • Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

    Peter C Fong;David S Boss;Timothy A Yap;Andrew Tutt

  • Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

    A Goldhirsch;E P Winer;A S Coates;R D Gelber

  • Pan-cancer analysis of whole genomes

    Peter J. Campbell;Gad Getz;Jan O. Korbel;Joshua M. Stuart

  • Landscape of somatic mutations in 560 breast cancer whole-genome sequences

    Serena Nik-Zainal;Serena Nik-Zainal;Helen Davies;Johan Staaf;Manasa Ramakrishna

  • Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

    Andrew Tutt;Mark Robson;Judy E Garber;Susan M Domchek

  • Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer

    A Tutt;M Robson;J E Garber;S M Domchek

  • Mutational Processes Molding the Genomes of 21 Breast Cancers

    Serena Nik-Zainal;Ludmil B. Alexandrov;David C. Wedge;Peter Van Loo;Peter Van Loo;Peter Van Loo

  • The landscape of cancer genes and mutational processes in breast cancer

    Philip J. Stephens;Patrick S. Tarpey;Helen Davies;Peter Van Loo;Peter Van Loo

  • Hallmarks of 'BRCAness' in sporadic cancers

    Nicholas Turner;Andrew Tutt;Alan Ashworth

  • 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

    F. Cardoso;A. Costa;E. Senkus;M. Aapro

  • The Life History of 21 Breast Cancers

    Serena Nik-Zainal;Peter Van Loo;Peter Van Loo;Peter Van Loo;David C. Wedge;Ludmil B. Alexandrov

  • Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.

    Nuala McCabe;Nicholas C. Turner;Christopher J. Lord;Katarzyna Kluzek

  • Triple negative tumours : a critical review

    J S Reis-Filho;Andrew Tutt;Andrew Tutt

  • De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

    G. Curigliano;H. J. Burstein;E. P. Winer;M. Gnant

  • Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

    Andrew N.J. Tutt;Judy E. Garber;Bella Kaufman;Giuseppe Viale

  • Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval

    Peter C. Fong;Timothy A. Yap;David S. Boss;Craig P. Carden

  • Definition of Clinically Distinct Molecular Subtypes in Estrogen Receptor–Positive Breast Carcinomas Through Genomic Grade

    Sherene Loi;Benjamin Haibe-Kains;Christine Desmedt;Françoise Lallemand

  • HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures

    Helen Davies;Dominik D. Glodzik;Sandro S. Morganella;Lucy R. Yates

Frequent Co-Authors

Alan Ashworth
Alan Ashworth University of California, San Francisco
Christopher J. Lord
Christopher J. Lord Institute of Cancer Research
Sarah E Pinder
Sarah E Pinder King's College London
Peter J. Campbell
Peter J. Campbell Wellcome Sanger Institute
Christos Sotiriou
Christos Sotiriou Université Libre de Bruxelles
Tony Ng
Tony Ng King's College London
Anne Lise Børresen-Dale
Anne Lise Børresen-Dale Oslo University Hospital
Andrea L. Richardson
Andrea L. Richardson Johns Hopkins University
Judith M. Bliss
Judith M. Bliss Institute of Cancer Research

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering a future in medicine but aren't pursuing a traditional MD, a wide range of online healthcare degrees and career options are available. For those interested in nursing, pursuing the cheapest rn to bsn program can be a practical way to advance your credentials while saving on tuition costs.

Applicants with non-nursing backgrounds might find direct entry online msn programs especially appealing, as they allow entry into advanced nursing without a prior nursing degree. Alternatively, online adn programs for non nurses provide an accessible path for those looking to break into the nursing profession more quickly.

If patient care isn’t your main interest, you might consider the administrative and technology side of healthcare. Curious about financial options? Find out can you get financial aid for medical billing and coding online programs, which can lead to in-demand roles supporting medical practices.

Best Scientists Citing Andrew Tutt

Trending Scientists

Recently Published Articles